Farxiga (Dapagliflozin) Cost in Virginia: 2026 Pricing, Insurance, and Savings Guide

Farxiga is the brand name for dapagliflozin, an SGLT2 inhibitor tablet taken once daily. It is FDA-approved for three separate indications: improving glycemic control in type 2 diabetes, reducing hospitalization for heart failure with reduced ejection fraction, and slowing progression of chronic kidney disease. Dapagliflozin is also sold as Xigduo XR (combined with metformin) and Qtern (combined with saxagliptin); this article covers Farxiga alone, 10 mg tablets, for Virginia residents.

The direct answer

Farxiga has no FDA-approved generic in the United States as of this writing, so most Virginia patients without full insurance coverage pay a list-level cash price, though the exact dollar figure at any given pharmacy on any given day changes with manufacturer pricing and pharmacy markup and was not independently verified for this draft. What is stable and verifiable is the coverage structure: Virginia Medicaid covers Farxiga with prior authorization, commercial insurers generally place it on a preferred or non-preferred brand tier with prior authorization for the diabetes indication specifically, and the AstraZeneca manufacturer savings card is available only to commercially insured patients, not to anyone enrolled in Medicare, Medicaid, TRICARE, or VA benefits, because of federal anti-kickback rules. The single most useful thing a Virginia patient can do before assuming a price is to confirm which of Farxiga's three FDA indications applies to their prescription, since that indication often determines whether step therapy through metformin is required and how aggressively a plan reviews the prior authorization.

Why the indication matters more than the pharmacy

A common assumption is that Farxiga's price or approval difficulty depends mainly on which pharmacy or discount card a patient uses. The more consequential variable for Virginia patients is the FDA-labeled indication being treated. The FDA-approved prescribing information for Farxiga lists three indications: glycemic control in type 2 diabetes, reduction of heart failure hospitalization in adults with heart failure with reduced ejection fraction, and reduction of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with chronic kidney disease. Many commercial and Medicaid formularies apply step therapy (typically requiring a documented metformin trial or contraindication) for the diabetes indication, but several plans waive that step-therapy requirement for heart failure and CKD indications given the strength of the underlying trial evidence. This means two patients with identical insurance can face very different prior authorization timelines depending only on the diagnosis code attached to the prescription. Confirming this with the prescribing clinician and the plan's formulary document, rather than assuming coverage is uniform, is the single highest-value verification step.

What the trial evidence actually supports

Dapagliflozin's cardiovascular and renal indications rest on large randomized outcomes trials, not on the glycemic-control mechanism alone. A cardiovascular outcomes trial in patients with heart failure with reduced ejection fraction (commonly referenced as DAPA-HF, published in the New England Journal of Medicine in 2019) reported that dapagliflozin reduced a composite outcome of worsening heart failure events and cardiovascular death compared with placebo, in both diabetic and non-diabetic participants. A separate trial in chronic kidney disease (commonly referenced as DAPA-CKD, published in 2020) reported a reduction in a composite of sustained kidney function decline, kidney failure, and renal or cardiovascular death. Both trials are widely cited in cardiology and nephrology guidelines. The exact hazard ratios, confidence intervals, and effect sizes attributed to these trials in earlier promotional and educational material should be treated as needing verification against the original journal publications before being repeated as precise figures; this draft intentionally does not restate specific hazard ratios or investigator quotations that could not be confirmed against a verified copy of the source papers. SGLT2 inhibitors as a class carry a strong guideline endorsement for heart failure with reduced ejection fraction from major U.S. cardiology societies, which is one reason Virginia insurers often approve Farxiga for that indication with fewer administrative hurdles than for diabetes alone. Readers who need the precise trial statistics for a clinical decision should ask their prescriber to pull the original New England Journal of Medicine publications rather than relying on secondary summaries, including this one.

Virginia Medicaid coverage

Virginia Medicaid covers Farxiga but requires prior authorization before dispensing. The prescriber generally needs to document the diagnosis being treated, prior medication trials (such as a metformin trial for type 2 diabetes), and relevant lab values such as HbA1c or eGFR. Processing timelines, specific formulary tier placement, and the exact documentation checklist used by Virginia Medicaid's pharmacy benefit administrator change periodically and should be confirmed directly with the plan or the prescribing clinic rather than assumed from this article, since no primary Virginia Medicaid formulary document was available to verify current timelines for this draft.

The AstraZeneca savings card and federal program eligibility

AstraZeneca offers a manufacturer copay savings program for commercially insured patients, described on the company's own AZ&Me program page. A structural fact that is stable and verifiable, not date-sensitive, is that manufacturer copay cards cannot legally be used by patients enrolled in Medicare, Medicaid, TRICARE, or VA benefits, because federal anti-kickback statute rules prohibit manufacturers from subsidizing copays for federal health program beneficiaries. The specific dollar cap, annual maximum, and per-fill savings amount on the current AstraZeneca card change over time and should be confirmed on the manufacturer's site at the time of use rather than assumed from any fixed figure.

For Medicare Part D enrollees, a separate and independently verifiable federal fact applies: the Inflation Reduction Act created a $2,000 annual out-of-pocket cap on Part D drug spending, effective January 1, 2025, described on the CMS Inflation Reduction Act page. Once a Part D enrollee's out-of-pocket spending across all covered drugs reaches that cap in a calendar year, covered drugs cost nothing for the remainder of that year. How quickly a given patient reaches the cap depends on their plan's tier placement of Farxiga and their other medications, which is plan-specific and not something this article can state generically.

Is compounded dapagliflozin legal in Virginia?

Compounded dapagliflozin prepared by a licensed 503A compounding pharmacy under a valid patient-specific prescription is permitted under federal law, described in the FDA's guidance on compounding laws and policies, and Virginia-licensed pharmacies operate under the oversight of the Virginia Board of Pharmacy. Federal compounding rules generally restrict compounding a copy of a commercially available FDA-approved drug unless there is a documented clinical difference in dose, form, or a patient-specific need such as an allergy to an inactive ingredient. This is an important distinction from an FDA-approved generic: compounded dapagliflozin has not undergone FDA review for safety, efficacy, or manufacturing consistency, and it does not carry bioequivalence data. A clinician considering compounded dapagliflozin for a Virginia patient should document the specific clinical justification, and patients should understand that cost savings come with a real reduction in regulatory oversight, not just a different supply chain for the same product.

Telehealth prescribing in Virginia

Virginia permits licensed clinicians to establish a patient relationship through synchronous audio-video telehealth and prescribe non-controlled medications, which includes SGLT2 inhibitors like dapagliflozin, under guidance from the Virginia Board of Medicine. Because Farxiga carries labeled risks including diabetic ketoacidosis (including euglycemic DKA), genital mycotic infections, urinary tract infections, and volume depletion, particularly in patients over 65 or on loop diuretics, a responsible telehealth visit should include baseline and periodic renal function monitoring (eGFR, creatinine, potassium), obtained through a local lab draw. These safety considerations come directly from the FDA label and are not indication-specific; they apply whether Farxiga is being started for diabetes, heart failure, or CKD.

What is established, what is plausible, and what is not established

Established: dapagliflozin has three distinct FDA-approved indications, each supported by regulatory approval and referenced outcomes trials; federal law prohibits manufacturer copay card use by federal health program beneficiaries; the IRA's $2,000 Part D out-of-pocket cap took effect January 1, 2025; compounded dapagliflozin from a licensed 503A pharmacy is legal under specific federal and Virginia state conditions; Virginia permits telehealth prescribing of non-controlled medications including Farxiga.

Plausible but requiring current verification: any specific cash price, discount-card price, insurer copay amount, formulary tier, or Medicaid prior authorization turnaround time. These figures move with pharmacy, plan year, and manufacturer pricing decisions, and none were confirmed against a live source at the time this draft was prepared.

Not established from the material available: precise hazard ratios, p-values, or investigator quotations from the heart failure and CKD outcomes trials, since the original journal citations could not be verified against a confirmed primary source for this draft. Any number-for-number restatement of those trial results should be checked against the original New England Journal of Medicine publications before being used in patient-facing or clinical decision material.

Verification checklist: stable facts vs. facts that change

Consult this resource before discussing dapagliflozin costs or insurance coverage details with a patient or recording such information in the medical record.

Stable federal or clinical facts (unlikely to change month to month, but still confirm the date of your source):

• Farxiga's three FDA-approved indications (type 2 diabetes, HFrEF, CKD), verify against the current FDA label.
• No FDA-approved generic dapagliflozin exists in the U.S. as of this draft's date, verify current patent/generic status at fda.gov before relying on this.
• Manufacturer copay cards cannot be used by Medicare, Medicaid, TRICARE, or VA beneficiaries, this is a federal anti-kickback rule, not a plan-specific policy.
• The Medicare Part D $2,000 annual out-of-pocket cap took effect January 1, 2025, verify current-year cap amount at cms.gov, since it can adjust annually.
• Compounded dapagliflozin from a licensed 503A pharmacy is legal under FDA and Virginia Board of Pharmacy rules when clinically justified and patient-specific.
• Virginia permits telehealth prescribing of non-controlled medications including Farxiga.

Date-sensitive facts that must be reconfirmed at the point of care (do not repeat a fixed number without checking the live source):

• Current cash/list price for Farxiga 10 mg at a specific Virginia pharmacy.
• Current GoodRx, SingleCare, or RxSaver price at a specific ZIP code.
• Current AstraZeneca savings card maximum benefit and per-fill savings cap.
• Current AZ&Me patient assistance program income eligibility threshold.
• A specific insurer's (Anthem, Aetna, Cigna, UnitedHealthcare, Optima) current formulary tier and step-therapy requirement for Farxiga.
• Virginia Medicaid's current prior authorization documentation checklist and processing timeline.
• Any specific state employee health plan's current copay or tier placement.

If a number in this article or elsewhere cannot be matched to a source dated within the current plan year, treat it as an estimate, not a quote.

When to seek care rather than adjust a prescription yourself

Dapagliflozin carries a labeled risk of diabetic ketoacidosis that can occur even with near-normal blood glucose (euglycemic DKA). Symptoms such as nausea, vomiting, abdominal pain, fatigue, or difficulty breathing while taking Farxiga warrant urgent medical evaluation rather than waiting for a routine follow-up, regardless of insurance or cost circumstances. Cost-driven decisions such as switching to a compounded product, skipping doses to stretch a supply, or discontinuing therapy without medical guidance should be discussed with the prescribing clinician first, since abrupt discontinuation in a patient being treated for heart failure or CKD may carry its own clinical risk.